Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Pregnancy and Childbirth

Efficacy of chlorhexidine vaginal preparation in reducing postoperative infections during emergency cesarean deliveries for women in labor: a randomized controlled trial

  1. 1Obstetrics & Gynecology Department, Ministry of Defense Health Services, Armed Forces Hospitals Southern Region, Khamis Mushait, Saudi Arabia
  2. 2Obstetrics & Gynecology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  3. 3Obstetrics & Gynecology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt

Abstract

Background: Postoperative infections are a leading cause of maternal morbidity after emergency cesarean delivery. This trial explores the effectiveness of preoperative vaginal cleansing via the use of chlorhexidine for reducing these complications in women in labor.

Methods: This single-blinded superiority randomized controlled trial included 840 women in labor equally distributed to either immediate preoperative chlorhexidine gluconate 0.05% vaginal cleansing or no-cleansing; 826 were analyzed under a modified intention-to-treat approach. The co-primary outcomes were postcesarean endometritis and surgical site infection (SSI). Secondary outcomes included composite wound complications, postoperative fever, significant leukocytosis, hospital readmission, length of stay, and adverse drug reactions. Effects are expressed as risk ratios (RR) with 95% confidence intervals, with adjusted, sensitivity, and subgroup analyses for the co-primary outcomes.

Results: Chlorhexidine significantly reduced both co-primary outcomes; postcesarean endometritis (1.9% vs. 6.3%; RR 0.303, 95% CI 0.139–0.662; P = 0.001) and SSI (1.4% vs. 5.4%; RR 0.269, 95% CI 0.110–0.656; P = 0.002); both remained significant against a Bonferroni-adjusted threshold of 0.025. Other outcomes were also reduced, including composite wound complications (3.4% vs. 11.0%; RR 0.307, 95% CI 0.171–0.550; P < 0.001), and readmission for infection (1.4% vs. 6.3%; P < 0.001; RR 0.227, 95% CI 0.095–0.547). The co-primary outcome effects persisted after adjustment and in sensitivity analyses. Treatment effects were in the same direction across premature rupture of membranes (PROM) and obesity subgroups with no significant interaction, although the SSI reduction reached significance overall and in the non-obese stratum but not within the obese stratum.

Conclusion: In this single-center trial, preoperative chlorhexidine vaginal cleansing produced lower rates of postcesarean endometritis and SSI and of related infectious morbidity. As a low-cost intervention that can be integrated into existing perioperative workflows, it is a promising strategy for reducing maternal infection; however, adverse events were not systematically solicited, and neonatal exposure was not assessed. Multicenter confirmation, systematic maternal and neonatal safety data, and cost-effectiveness analysis are required before routine adoption.

Trial registration: ClinicalTrials.gov NCT04385680 submitted 9 May 2020, first posted 13 May 2020.

Supplementary information: The online version contains supplementary material available at https://doi.org/10.1186/s12884-026-10027-1.

Related

  1. Chlorhexidine Versus Iodine-Based Skin Preparation Was Not Associated with a Significant Difference in 90-Day Infection Risk After Instrumented Degenerative Cervical or Lumbar Spine Surgery: A Propensity Score-Matched Analysis
    Firas Batrash, Fahad Jamal, Siddharth Jasti +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Surgery & anaesthesiaCrossref
  2. Applicator-Based Versus Bulk-Bottle Delivery of the Same Alcoholic Chlorhexidine: A Single-Center, Non-Randomized Pilot Micro-Costing Study of Two Surgical Skin-Antisepsis Workflows.
    Francisco Guillen-Grima, Maria Pilar Garcia-Garcia, Laura Guillen-Aguinaga +3
    Healthcare (Basel, Switzerland)Peer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Comparative Clinical Efficacy of HYBENX® Versus Chlorhexidine Gel as Adjuncts to Scaling and Root Planing: A Split-Mouth Randomized Pilot Clinical Trial.
    Malaz Fayad, Hashem Daoud
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Chlorhexidine within a standardized oral-care bundle for the prevention of ventilator-associated pneumonia: a pragmatic cluster-randomized crossover trial in six medical intensive care units.
    S Anushapreethi, Pritam Chhotray, Samir Samal +3
    Critical care (London, England)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  5. Postoperative infections following silicone implant-based gluteal augmentation
    Elisa Bertulla, Francesca Maria Scura, Edoardo Raposio
    JPRAS openPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
BibTeX
@article{atia2026efficacy,
  title = {{Efficacy of chlorhexidine vaginal preparation in reducing postoperative infections during emergency cesarean deliveries for women in labor: a randomized controlled trial}},
  author = {Hytham Atia and Abdelrahman Saleh and Mohamed Ibrahim and Ahmed Shafik},
  journal = {BMC Pregnancy and Childbirth},
  year = {2026},
  month = oct,
  doi = {10.1186/s12884-026-10027-1},
  url = {https://doi.org/10.1186/s12884-026-10027-1},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Efficacy of chlorhexidine vaginal preparation in reducing postoperative infections during emergency cesarean deliveries for women in labor: a randomized controlled trial
AU  - Hytham Atia
AU  - Abdelrahman Saleh
AU  - Mohamed Ibrahim
AU  - Ahmed Shafik
PY  - 2026
DA  - 2026/10/28
JO  - BMC Pregnancy and Childbirth
DO  - 10.1186/s12884-026-10027-1
UR  - https://doi.org/10.1186/s12884-026-10027-1
AB  - Background: Postoperative infections are a leading cause of maternal morbidity after emergency cesarean delivery. This trial explores the effectiveness of preoperative vaginal cleansing via the use of chlorhexidine for reducing these complications in women in labor.  Methods: This single-blinded superiority randomized controlled trial included 840 women in labor equally distributed to either immediate preoperative chlorhexidine gluconate 0.05% vaginal cleansing or no-cleansing; 826 were analyzed under a modified intention-to-treat approach. The co-primary outcomes were postcesarean endometritis and surgical site infection (SSI). Secondary outcomes included composite wound complications, postoperative fever, significant leukocytosis, hospital readmission, length of stay, and adverse drug reactions. Effects are expressed as risk ratios (RR) with 95% confidence intervals, with adjusted, sensitivity, and subgroup analyses for the co-primary outcomes.  Results: Chlorhexidine significantly reduced both co-primary outcomes; postcesarean endometritis (1.9% vs. 6.3%; RR 0.303, 95% CI 0.139–0.662; P = 0.001) and SSI (1.4% vs. 5.4%; RR 0.269, 95% CI 0.110–0.656; P = 0.002); both remained significant against a Bonferroni-adjusted threshold of 0.025. Other outcomes were also reduced, including composite wound complications (3.4% vs. 11.0%; RR 0.307, 95% CI 0.171–0.550; P < 0.001), and readmission for infection (1.4% vs. 6.3%; P < 0.001; RR 0.227, 95% CI 0.095–0.547). The co-primary outcome effects persisted after adjustment and in sensitivity analyses. Treatment effects were in the same direction across premature rupture of membranes (PROM) and obesity subgroups with no significant interaction, although the SSI reduction reached significance overall and in the non-obese stratum but not within the obese stratum.  Conclusion: In this single-center trial, preoperative chlorhexidine vaginal cleansing produced lower rates of postcesarean endometritis and SSI and of related infectious morbidity. As a low-cost intervention that can be integrated into existing perioperative workflows, it is a promising strategy for reducing maternal infection; however, adverse events were not systematically solicited, and neonatal exposure was not assessed. Multicenter confirmation, systematic maternal and neonatal safety data, and cost-effectiveness analysis are required before routine adoption.  Trial registration: ClinicalTrials.gov NCT04385680 submitted 9 May 2020, first posted 13 May 2020.  Supplementary information: The online version contains supplementary material available at https://doi.org/10.1186/s12884-026-10027-1.
SN  - 1471-2393
ER  -